PL1773450T3 - Kompozycja farmaceutyczna - Google Patents

Kompozycja farmaceutyczna

Info

Publication number
PL1773450T3
PL1773450T3 PL05763958T PL05763958T PL1773450T3 PL 1773450 T3 PL1773450 T3 PL 1773450T3 PL 05763958 T PL05763958 T PL 05763958T PL 05763958 T PL05763958 T PL 05763958T PL 1773450 T3 PL1773450 T3 PL 1773450T3
Authority
PL
Poland
Prior art keywords
therapeutically
combinations
betaine
administration
cholesterol
Prior art date
Application number
PL05763958T
Other languages
English (en)
Inventor
Jallal Messadek
Original Assignee
Jallal Messadek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jallal Messadek filed Critical Jallal Messadek
Publication of PL1773450T3 publication Critical patent/PL1773450T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05763958T 2004-07-22 2005-07-13 Kompozycja farmaceutyczna PL1773450T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BE2004/0364A BE1016128A6 (fr) 2004-07-22 2004-07-22 Combinaisons therapeutiques
EP05763958A EP1773450B1 (fr) 2004-07-22 2005-07-13 Combinaisons therapeutiques
PCT/BE2005/000112 WO2006007671A2 (fr) 2004-07-22 2005-07-13 Combinaisons therapeutiques

Publications (1)

Publication Number Publication Date
PL1773450T3 true PL1773450T3 (pl) 2011-07-29

Family

ID=35462104

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05763958T PL1773450T3 (pl) 2004-07-22 2005-07-13 Kompozycja farmaceutyczna

Country Status (10)

Country Link
US (1) US20070134324A1 (pl)
EP (1) EP1773450B1 (pl)
AT (1) ATE498427T1 (pl)
BE (1) BE1016128A6 (pl)
DE (1) DE602005026394D1 (pl)
DK (1) DK1773450T3 (pl)
ES (1) ES2361284T3 (pl)
PL (1) PL1773450T3 (pl)
PT (1) PT1773450E (pl)
WO (1) WO2006007671A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
ES2278314T3 (es) * 2003-04-17 2007-08-01 Jallal Messadek Formulaciones orales para la liberacion controlada de la betaina.
US7785740B2 (en) 2004-04-09 2010-08-31 Air Products And Chemicals, Inc. Overcharge protection for electrochemical cells
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
BRPI0610249A2 (pt) 2005-04-27 2010-06-08 Jallal Messadek associação ou combinação farmacêutica, composição farmacêutica, processo de co-cristalização e o uso de insulina ou análogo de insulina
CA2679403A1 (en) * 2007-03-01 2008-09-04 Concourse Health Sciences Llc Isomers of inositol niacinate and uses thereof
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
CN102421421A (zh) * 2009-05-12 2012-04-18 Bpsi控股有限责任公司 含有抗黏性剂细微颗粒的包衣和覆有该包衣的基体
WO2010132204A1 (en) 2009-05-12 2010-11-18 Bpsi Holdings, Llc. Enhanced moisture barrier immediate release film coating systems and substrates coated therewith
KR101296328B1 (ko) * 2009-09-21 2013-08-14 주식회사 삼양바이오팜 피브레이트계 약물을 포함하는 고체분산체 및 이의 제조방법

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US580098A (en) * 1897-04-06 Governor for water-motors
US3577534A (en) * 1968-06-20 1971-05-04 Canada Packers Ltd Stable orally active heparinoid complexes
GB1509979A (en) * 1975-11-28 1978-05-10 Fisons Ltd Pharmaceutical compositions containing aspirin or indomethacin
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4605548A (en) * 1983-05-31 1986-08-12 Nitto Electric Industrial Co., Ltd. Drug administration material
GB8325627D0 (en) * 1983-09-24 1983-10-26 Scras Therapeutic compositions
DK162986A (da) * 1985-04-12 1986-10-13 Forest Laboratories Terapeutisk middel i enhedsdosisform
AU607172B2 (en) * 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
US4902718A (en) * 1988-04-08 1990-02-20 Bayless Robert K Calcium homeostasis compositions and methods for controlling calcium metabolism
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5405614A (en) * 1992-04-08 1995-04-11 International Medical Associates, Inc. Electronic transdermal drug delivery system
US5342621A (en) * 1992-09-15 1994-08-30 Advanced Cardiovascular Systems, Inc. Antithrombogenic surface
US5876780A (en) * 1993-04-29 1999-03-02 Cultor, Ltd. Compositions for treating coccidiosis
US5716941A (en) * 1993-07-07 1998-02-10 Biogenesys Use of methyl donor compounds to treat neurological dysfunction associated with immune defects
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US6355166B1 (en) * 1994-08-25 2002-03-12 The University Of Iowa Research Foundation Magnetically enhanced composite materials and methods for making and using the same
US6056958A (en) * 1994-12-09 2000-05-02 Dupont Pharmaceuticals Method of treatment of arterial and venous thromboembolic disorders
US5961999A (en) * 1995-06-08 1999-10-05 Wella Aktiengesellschaft Method of skin care using a skin care preparation containing a betaine ester and an α-hydroxy acid
US6162926A (en) * 1995-07-31 2000-12-19 Sphere Biosystems, Inc. Multi-substituted fullerenes and methods for their preparation and characterization
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
AU2260397A (en) * 1996-01-31 1997-08-22 Trustees Of The University Of Pennsylvania, The Remote control drug delivery device
US5688499A (en) * 1996-03-13 1997-11-18 Queen's University At Kingston Antagonism of endothelin actions
US5880098A (en) * 1996-04-12 1999-03-09 Pharmacia & Upjohn Aktiebolag Therapeutic treatment
IL119029A0 (en) * 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US7608640B2 (en) * 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
BE1012495A3 (fr) * 1999-03-02 2000-11-07 Messadek Jallal La glycine-betaine pour son usage antithrombotique.
DE19910682B4 (de) * 1999-03-10 2004-09-02 Dierkes, Jutta, Dr. Verwendung eines Kombinationspräparates zur Therapie einer Fibrat-induzierten Hyperhomocysteinämie
CA2407027C (en) * 2000-04-20 2011-02-15 Rtp Pharma Inc. Improved water-insoluble drug particle process
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
FR2811227A1 (fr) * 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
WO2002042272A2 (en) * 2000-11-20 2002-05-30 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
FI114538B (fi) * 2001-01-12 2004-11-15 Finnfeeds Finland Ltd Glysiinibetaiinin käyttö verenpainetta alentavan tuotteen valmistukseen
EP1408949B1 (en) * 2001-02-05 2007-12-19 Jallal Messadek Glycine betaine and its use as anti-hemorrhagic agent
GB0108930D0 (en) * 2001-04-10 2001-05-30 Boots Co Plc Therapeutic agents
US20040072750A1 (en) * 2001-05-03 2004-04-15 David Phillips Compounds and methods for the modulation of CD154
US6531171B2 (en) * 2001-07-03 2003-03-11 Nutricia Usa, Inc. Food products containing betaine
US20060160896A1 (en) * 2002-02-04 2006-07-20 Jallal Messadek Therapeutic treatment
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
EP2402753A1 (en) * 2002-03-11 2012-01-04 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
DE60238283D1 (de) * 2002-11-25 2010-12-23 Jallal Messadek Betain und Salicylsäure Zusammensetzungen
ES2278314T3 (es) * 2003-04-17 2007-08-01 Jallal Messadek Formulaciones orales para la liberacion controlada de la betaina.
US7097968B2 (en) * 2003-07-10 2006-08-29 General Atomics Methods and compositions for assaying homocysteine
US20060128657A1 (en) * 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
CA2534660A1 (en) * 2003-08-05 2005-02-10 Galephar M/F Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent
US7115947B2 (en) * 2004-03-18 2006-10-03 International Business Machines Corporation Multiple dielectric finfet structure and method

Also Published As

Publication number Publication date
BE1016128A6 (fr) 2006-03-07
WO2006007671A3 (fr) 2006-02-23
DK1773450T3 (da) 2011-06-14
ATE498427T1 (de) 2011-03-15
EP1773450B1 (fr) 2011-02-16
DE602005026394D1 (de) 2011-03-31
ES2361284T3 (es) 2011-06-15
WO2006007671A2 (fr) 2006-01-26
EP1773450A2 (fr) 2007-04-18
US20070134324A1 (en) 2007-06-14
PT1773450E (pt) 2011-05-18

Similar Documents

Publication Publication Date Title
PT1773450E (pt) Composi??es terap?uticas
WO2006041641A3 (en) Therapeutic agents with decreased toxicity
MX2007007885A (es) Composiciones farmaceuticas oralmente desintegrables con agentes de indicacion sensorial.
WO2005112633A3 (en) Compounds and compositions for delivering active agents
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
TW200716157A (en) Pharmaceutical formulations and methods of treatment using the same
MX2007003078A (es) Compuestos de imidazoquinolina.
WO2005016286A3 (en) Pyrazine modulators of cannabinoid receptors
AU7315301A (en) Compounds and compositions for delivering active agents
WO2006007312A3 (en) Co-administration of dehydroepiandrosterone (dhea) congener with pharmaceutically active agents for treating inflammation
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
DK1965797T3 (da) Nedsættelse af svimmelhed, en bivirkning forbundet med pirfenidonterapi
UA103614C2 (uk) Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки
MX2007007504A (es) Composiciones terapeuticas para la administracion intranasal de ketorolaco.
WO2005074536A3 (en) Compositions and methods using proton pump inhibitors
MX2009013779A (es) Uso de agonistas de tlr y/o interferonas tipo 1 para aliviar la toxicidad de los regimenes terapeuticos de agonistas de tnf-r.
WO2005123192A3 (en) Improving pain treatment with strontium combinations
MY149911A (en) Methods for administering long-lasting hypoglycemic agents
WO2008144269A3 (en) Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
LU92202I9 (pl)
WO2009023355A3 (en) Compositions and methods for reducing the toxicity of certain toxins
TNSN07203A1 (en) Pharmaceutical compositions for the treatment of cellulite
WO2005009363A3 (en) Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies